Benznidazol (Ro 07-1051) is an antiparasitic medication, with an IC₅₀ of 20.35 μM for Colombian T. cruzi strains, and has been used in the treatment of Chagas disease^[1][2]. In Vivo: Benznidazole (100 mg/kg/day, p.o., 30 days) produces a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart, in mice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12 isolate and treated at 180 days post infection (p.i.) (i.e. chronic phase) with Benznidazole^[1].